Evalve clinical trial

Epub Aug Drug-Eluting Stents. National Library of Medicine U. National Institutes of Health U. Department of Health and Human Services. The safety and scientific validity of this study is the responsibility of the study sponsor and investigators.

Coronary Artery Disease. Phase 3. Study Type :. Interventional Clinical Trial. Actual Enrollment :. Study Start Date :. Actual Primary Completion Date :. Actual Study Completion Date :. Washington, District of Columbia, United States, This bone disease may cause bone pain, fractures, and poor formation of red blood cells. Other problems from secondary HPT may include increases in blood levels of calcium and phosphorus.

These may cause calcium to deposit in body tissues. Calcium deposits can cause arthritis joint pain and swelling , muscle inflammation, itching, gangrene death of soft tissue , or heart and lung problems. New evidence suggests that secondary HPT is associated with cardiovascular disease and increased death risk. These events include death from any reason, heart attack and episodes where the heart does not get enough oxygen, peripheral vascular disease narrowing of vessels that carry blood to the legs, arms, stomach or kidneys , and heart failure a condition that occurs when the heart is unable to pump enough blood to meet the need's of the body's tissues.

FDA Resources. Arms and Interventions. Possible doses: 30, 60, 90, , and mg using tablet strengths of 30, 60, or 90 mg. Outcome Measures. Time to Myocardial Infarction. Time to Hospitalization for Unstable Angina.

Time to Heart Failure. Time to Peripheral Vascular Event. Time to Cardiovascular Mortality. Time to Stroke. Time to Bone Fracture. Time to Parathyroidectomy. Eligibility Criteria.

Information from the National Library of Medicine Choosing to participate in a study is an important personal decision. Myocardial ischemia b. Unstable angina c. Heart Failure HF including any unplanned presentation to a health care facility that would require mechanical intervention [i. Peripheral vascular disease other than dialysis vascular access revision e. Stroke History of seizure within 12 weeks prior to randomization Scheduled date for kidney transplant from a known living donor Anticipated parathyroidectomy within 6 months after randomization in all instances, the 2 refers to squared.

Conclusions and relevance: Galcanezumab mg and mg monthly injections provided clinical benefits and improved functioning. The incidence rate of adverse events was low, demonstrating the favorable tolerability profile of galcanezumab. Trial registration: ClinicalTrials. Abstract Importance: Migraine is a disabling neurological disease characterized by severe headache attacks.

Publication types Randomized Controlled Trial. National Institutes of Health U. Department of Health and Human Services. The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Atherosclerotic Lesion s. Phase 3. Study Type :. Interventional Clinical Trial. Actual Enrollment :.

Study Start Date :. Actual Primary Completion Date :.